Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Alexion Promotes Kimihiro Kasamo to Japan Chief
July 18, 2019
- Bayer Flatly Denies Its Employee’s Allegations in 2nd Oral Proceedings for Damage Suit
July 18, 2019
- Takeda Gears Up for Clinical Testing of 1st iPS-Derived CAR-T, Eyes Trial Launch in 2021
July 17, 2019
- Takeda Launches New Manufacturing Facility for Ninlaro at Irish Plant
July 17, 2019
- JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
July 16, 2019
- 60% of Japan Diabetes Patients Bear CV Risk Factors, or Suffered Event: Novo
July 16, 2019
- Simone Thomsen Tapped as Lilly Japan Chief; Patrik Jonsson to Take Big Job at HQ
July 12, 2019
- Ono Snags Stanford Spinout’s Macrophage Checkpoint in Asia
July 12, 2019
- PeptiStar’s Peptides Manufacturing Plant Completed
July 11, 2019
- Eisai Opens New Dementia Research Center in Cambridge
July 11, 2019
- Tarlige Most Promoted Drug for GPs in March: Anterio
July 11, 2019
- Astellas’ JAK Inhibitor Smyraf Now Available for RA
July 11, 2019
- Fujifilm, Axcelead Team Up for iPS Cell-Based Drug Discovery Support
July 11, 2019
- Takeda Releases App for IBD Patients; Sharing Info with Doctors
July 11, 2019
- Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
- Sumitomo Dainippon, NCGM Launch AMR Project in Vietnam
July 10, 2019
- Riona Shows Non-Inferiority vs. Ferromia in Iron Deficiency Anemia: JT/Torii
July 10, 2019
- Long-Term Efficacy, Safety Confirmed for Hemlibra: Roche/Chugai
July 10, 2019
- Large-Scale Study Unveils 14.7% of Ovarian Cancer Patients Carry BRCA Mutations in Japan: AstraZeneca
July 10, 2019
- Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
July 9, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…